c19early.org COVID-19 treatment researchSA58SA58 (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

Loading...
 
More
 

Supplementary Data — SA58 reduced COVID-19 risk: real-time meta analysis of 3 studies

@CovidAnalysis, June 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang 34% 0.66 [0.55-0.80] cases 44/70 343/362 Improvement, RR [CI] Treatment Control Song (SB RCT) 81% 0.19 [0.08-0.48] symp. case 824 (n) 299 (n) Song (SB RCT) 62% 0.38 [0.23-0.62] cases 824 (n) 299 (n) Si 78% 0.22 [0.10-0.48] cases 3,368 (all patients) SA58 COVID-19 outcomes c19early.org June 2025 Favors SA58 Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit